PDS Biotechnology Corp Chief Medical Officer Kirk V. Shepard filed a Form 4 on November 17, 2026, disclosing the grant of 750,000 employee stock options on November 16, 2026, subject to stockholder approval of the company's 2026 Equity Incentive Plan.

Key Highlights

  • Grant date: November 16, 2026, with an exercise price of $0.9241 per share.
  • Option size: 750,000 shares of common stock underlying the employee stock option (right to buy).
  • Stockholder approval required: The option is not exercisable until stockholder approval of the 2026 Equity Incentive Plan is obtained under Nasdaq Marketplace Rule 5635(c).
  • Vesting schedule: Contingent on stockholder approval, shares vest in equal monthly installments over four years, beginning December 16, 2026, subject to continued service.
  • Cancellation provision: If stockholder approval is not obtained, Shepard must surrender the option to the company for cancellation.
  • Price of derivative security: $0, as reported in the filing.
  • Beneficial ownership following transaction: 750,000 derivative securities held directly.

PDS Biotechnology CMO Option Grant Details and Conditions

According to the Form 4 filed with the SEC on November 17, 2026, Kirk V. Shepard, Chief Medical Officer of PDS Biotechnology Corp (NASDAQ:PDSB), was granted an employee stock option to purchase 750,000 shares of common stock on November 16, 2026. The exercise price of the option is $0.9241 per share, and the option carries an expiration date of November 16, 2036, the filing states.

The filing notes that the grant is subject to stockholder approval of the issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c), and that "the option is not exercisable until stockholder approval has been obtained." Should stockholder approval be obtained, the filing states that the shares subject to the option "shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."

The filing further discloses that if stockholder approval is not obtained pursuant to the terms of the grant, "the Reporting Person shall surrender the option to the Company for cancellation." The price of the derivative security is reported as $0. The filing was signed by Spencer Brown as Attorney-in-Fact on November 17, 2026. No transactions in non-derivative securities were reported in Table I.

What Was Disclosed

Kirk V. Shepard, CMO of PDS Biotechnology Corp, disclosed receipt of a stock option for 750,000 shares at $0.9241, granted November 16, 2026, contingent on stockholder approval of the 2026 Equity Incentive Plan, with four-year monthly vesting beginning December 16, 2026.